Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $3.1200 (0.65%) ($3.1200 - $3.1200) on Wed. Jan. 12, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.67% (three month average) | RSI | 33 | Latest Price | $3.1200(0.65%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | HTBX declines -6.5% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) EEM(53%) VWO(53%) BLOK(51%) IBUY(51%) LIT(51%) | Factors Impacting HTBX price | HTBX will decline at least -1.835% in a week (0% probabilities). VXX(-48%) VIXM(-42%) UUP(-21%) TLT(-11%) GLD(-8%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.835% (StdDev 3.67%) | Hourly BBV | 1.1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-18(-676.92%) | Resistance Level | $3.45 | 5 Day Moving Average | $3.09(0.97%) | 10 Day Moving Average | $3.16(-1.27%) | 20 Day Moving Average | $3.45(-9.57%) | To recent high | -47.5% | To recent low | 3% | Market Cap | $343m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |